Evidence for the use of activated prothrombin complex concentrates (aPCCs) in the treatment of patients with haemophilia and inhibitors

Abstract

FEIBA™ and Autoplex®T have been used to control bleeding in patients with factor VIII or IX inhibitors for over 25 years. The major components of FEIBA™ are thought to be activated factor X and prothrombin, whereas the main active components in Autoplex®T are thought to be activated factors IX and VII. Both products have been found to effectively control approximately 80% of bleeds involving joints and soft tissues. Published experience of their use in surgery is limited. Thrombotic complications have been reported with high dose FEIBA™ therapy and have led to maximum dosage guidelines for this product. Copyright © 2002 S. Karger AG.